Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type ALK, Wild type EGFR status confers therapeutic sensitivity to Carboplatin, Durvalumab, Tremelimumab in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
IMFINZI (durvalumab) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.